title: Reduced thalamic volume in patients with chronic schizophrenia after switching from typical antipsychotic medications to olanzapine.
abstract: OBJECTIVE
  The authors performed a longitudinal study of the effects on thalamic volume of switching from typical to atypical antipsychotic medications.
  
  
  METHODS
  Magnetic resonance imaging scans were acquired from 10 subjects with chronic schizophrenia taking typical antipsychotics and 20 healthy volunteers. Subjects with schizophrenia were switched to olanzapine; both groups were rescanned.
  
  
  RESULTS
  At baseline, thalamic volumes in subjects with chronic schizophrenia were 5.8% greater than those of healthy volunteers. At follow-up, there was no significant difference between groups. Additional analysis revealed a significant positive correlation between baseline thalamic volume and dosage of typical antipsychotic medication. Higher dosages at baseline were correlated with larger reductions in volume after the switch to olanzapine.
  
  
  CONCLUSIONS
  Antipsychotic medication effects may be a factor in the wide range of thalamic volume differences reported between subjects with schizophrenia and healthy volunteers.
authors.affiliation: Centre for Complex Disorders, VGH Research Pavilion, Rm. 203-828 West 10th Ave., Vancouver, BC, Canada V5Z 1L8.
authors.forename: Babak
authors.initials: B
authors.lastname: Khorram
authors.forename: Donna J
authors.initials: DJ
authors.lastname: Lang
authors.forename: Lili C
authors.initials: LC
authors.lastname: Kopala
authors.forename: Robert A
authors.initials: RA
authors.lastname: Vandorpe
authors.forename: Qing
authors.initials: Q
authors.lastname: Rui
authors.forename: Vina M
authors.initials: VM
authors.lastname: Goghari
authors.forename: Geoffrey N
authors.initials: GN
authors.lastname: Smith
authors.forename: William G
authors.initials: WG
authors.lastname: Honer
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001284:Atrophy; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D002746:Chlorpromazine / Q000009:adverse effects / Q000627:therapeutic use; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006984:Hypertrophy; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D008297:Male; D000077152:Olanzapine; D012559:Schizophrenia / Q000188:drug therapy* / Q000473:pathology*; D013788:Thalamus / Q000187:drug effects / Q000473:pathology*; D013810:Therapeutic Equivalency
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine; D002746:Chlorpromazine